(Q28283836)

9

Susan O'Brien

0 references

Elias Jabbour

4

Elias Jabbour

0 references

Farhad Ravandi

11

Farhad Ravandi

0 references

Sherry Pierce

8

Sherry Pierce

0 references

Guillermo Garcia-Manero

7

Guillermo Garcia-Manero

0 references

Jorge Eduardo Cortes

1 reference

ORCID Public Data File 2021

Jean-Pierre J Issa

3

Jean-Pierre Issa

0 references

Deborah A McCue

6

Deborah McCue

0 references

author name string

G Nicolas Batty

1

0 references

Fabio P S Santos

5

0 references

Jorge E Cortés

Clinical Lymphoma, Myeloma & Leukemia

10

0 references

language of work or name

English

0 references

publication date

June 2010

0 references

published in

0 references

volume

10

0 references

issue

3

0 references

page(s)

205-10

0 references

cites work

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

5-Azacytidine and renal tubular dysfunction.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Estimation of creatinine clearance in morbidly obese patients

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726276

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20511166